EP
CPRX

Eudaimonia Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Eudaimonia Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$5K – 562
2021
Q1 		$5K Buy
+1,000
New +$3.97K ﹤0.01% 1319

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eudaimonia Partners's CPRX Position: Q2 2021 in Review

Eudaimonia Partners sold out of Catalyst Pharmaceutical (CPRX) in Q2 2021, closing a stake of 1,000 shares — an estimated $5K sold.

Eudaimonia Partners first reported a position in CPRX in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 139 funds tracked by Wall St. Rank hold CPRX as of Q2 2021.

  • Eudaimonia Partners reported no remaining Catalyst Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 1,000 Catalyst Pharmaceutical shares in Q2 2021, an estimated $5K.
  • Eudaimonia Partners first reported a position in Catalyst Pharmaceutical in Q1 2021 and held it in 1 quarter.
  • Eudaimonia Partners's Catalyst Pharmaceutical position peaked at $5K in Q1 2021.
  • 139 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.